These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Paliperidone as an alternative for risperidone in a case of schizophrenia with retrograde ejaculation. Kandasamy A J Neuropsychiatry Clin Neurosci; 2012; 24(3):E17-8. PubMed ID: 23037663 [No Abstract] [Full Text] [Related]
3. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY. Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Steen Andersen H; Eramo A; Hansen K; Naber D Int Clin Psychopharmacol; 2017 May; 32(3):147-154. PubMed ID: 28252452 [TBL] [Abstract][Full Text] [Related]
4. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. Westheide J; Cvetanovska G; Albrecht C; Bliesener N; Cooper-Mahkorn D; Creutz C; Hornung WP; Klingmüller D; Lemke MR; Maier W; Schubert M; Sträter B; Kühn KU J Sex Med; 2008 Dec; 5(12):2816-26. PubMed ID: 18466271 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. Rossenu S; Cleton A; Hough D; Crauwels H; Vandebosch A; Berwaerts J; Eerdekens M; Herben V; De Meulder M; Remmerie B; Francetic I Clin Pharmacol Drug Dev; 2015 Jul; 4(4):270-8. PubMed ID: 27136907 [TBL] [Abstract][Full Text] [Related]
6. Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels. Ahl J; Kinon BJ; Liu-Seifert H Ann N Y Acad Sci; 2004 Dec; 1032():289-90. PubMed ID: 15677431 [TBL] [Abstract][Full Text] [Related]
8. Paliperidone palmitate use in pregnancy in a woman with schizophrenia. Özdemir AK; Pak ŞC; Canan F; Geçici Ö; Kuloğlu M; Gücer MK Arch Womens Ment Health; 2015 Oct; 18(5):739-40. PubMed ID: 25599999 [TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement. Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616 [TBL] [Abstract][Full Text] [Related]
10. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia. Jarema M; Bieńkowski P; Heitzman J; Parnowski T; Rybakowski J Psychiatr Pol; 2017 Feb; 51(1):7-21. PubMed ID: 28455891 [TBL] [Abstract][Full Text] [Related]
11. Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient. Nakamura M; Fujita Y; Nagamine T Asia Pac Psychiatry; 2018 Mar; 10(1):. PubMed ID: 29314615 [No Abstract] [Full Text] [Related]
12. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone. Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988 [TBL] [Abstract][Full Text] [Related]
13. Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia. Owen RT Drugs Today (Barc); 2010 Jul; 46(7):463-71. PubMed ID: 20683501 [TBL] [Abstract][Full Text] [Related]
14. Paliperidone-Related Sudden Elevation of Plasma D-Dimer Levels: A Case Report. Wu C; Lai J; Ma S; Huang M; Hu S; Xu Y J Clin Psychopharmacol; 2020; 40(5):506-507. PubMed ID: 32826483 [No Abstract] [Full Text] [Related]
15. Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. Martínez-Andrés JA; García-Carmona JA Schizophr Res; 2019 Oct; 212():234-236. PubMed ID: 31421972 [No Abstract] [Full Text] [Related]
16. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study. Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study. Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570 [TBL] [Abstract][Full Text] [Related]
18. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756 [TBL] [Abstract][Full Text] [Related]
19. [The three-monthly paliperidone palmitate depot in the treatment of schizophrenia]. Spoelstra SK; Bais L; Knegtering H Tijdschr Psychiatr; 2018; 60(12):827-833. PubMed ID: 30536295 [TBL] [Abstract][Full Text] [Related]
20. A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates. Bressington D; Stock J; Hulbert S; MacInnes D Int Clin Psychopharmacol; 2015 Jul; 30(4):230-6. PubMed ID: 25882381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]